Ascletis Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA ...Middle East

HANGZHOU, China and SHAOXING, China, Nov. 28, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19, has...

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA )

Also on site :

• Numbrix 9 - June 18
• BACK
• A look at six bills in Albany awaiting Gov. Hochul’s signature